The effects of prostaglandin E1 on interleukin-6, pulmonary function and postoperative recovery in oesophagectomised patients

Anaesthesia and Intensive Care

Volumn 37, Issue 6, 2009, Pages 937-943

  Farrokhnia, F ^a,b   Makarem, J ^a,b   Khan, Z H ^a   Mohagheghi, M ^a,c   Maghsoudlou, M ^a,c   Abdollahi, A ^a,c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b Anesthesiology and Intensive Care Department   (Iran)

^c Department of Surgery ^*

Author keywords

Interleukin; Oesophagectomy; Postoperative complication; Pulmonary function

Indexed keywords

BUPIVACAINE; CISATRACURIUM; FENTANYL; INTERLEUKIN 6; MIDAZOLAM; MORPHINE SULFATE; PLACEBO; PROSTAGLANDIN E1; THIOPENTAL; OXYGEN; VASODILATOR AGENT;

ADULT; AGED; ANESTHESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESOPHAGUS RESECTION; FATTY ACID BLOOD LEVEL; FEMALE; HEMODYNAMICS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LUNG FUNCTION; MALE; NEOPLASM; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; BLOOD; BLOOD GAS ANALYSIS; CONVALESCENCE; ESOPHAGUS TUMOR; FORCED EXPIRATORY VOLUME; LENGTH OF STAY; METABOLISM; METHODOLOGY; MIDDLE AGED; PEROPERATIVE CARE; VITAL CAPACITY;

AGED; ALPROSTADIL; BLOOD GAS ANALYSIS; DOUBLE-BLIND METHOD; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; INTRAOPERATIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; OXYGEN; POSTOPERATIVE PERIOD; RECOVERY OF FUNCTION; VASODILATOR AGENTS; VITAL CAPACITY;

EID: 74049095593     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0903700618     Document Type: Article

References (42)

1. Altorki N, Kent M, Ferrara C, Port J. Three field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236:177-183.
2. Tandon S, Batchelor A, Bullock R, Gascoigne A, Griffin M, Hayes N et al. Peri-operative risk factors for acute lung injury following elective oesophagectomy. Br J Anaesth 2001; 86:633-638.
3. Millikan KW, Silverstein J, Hart V, Blair K, Bines S, Roberts J et al. A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. Arch Surg 1995; 130:617-624.
4. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220:364-373.
5. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, Le Saffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 1992; 216:583-590.
6. Bousamra M, Haasler GB, Parviz M. A decade of experience with transthoracic and transhiatal esophagectomy. Am J Surg 2002; 183:162-167.
7. Baudouin SV. Lung injury after thoracotomy. Br J Anaesth 2003; 91:132-142.
8. Ferguson MK, Martin TR, Reeder LB, Olak J. Mortality after esophagectomy: risk factor analysis. World J Surg 1997; 21:599-603.
9. 1 on inflammatory responses and gas exchange in patients undergoing surgery for oesophageal cancer. Br J Anaesth 2004; 93:199-203.
10. Abe T, Oka M, Tangoku A, Hayashi H, Yamamoto K, Yahara N et al. Interleukin-6 production in lung tissue after transthoracic esophagectomy. J Am Coll Surg 2001; 192:322-329.
11. Kooguchi K, Kobayashi A, Kitamura Y, Ueno H, Urata Y, Onodera H et al. Elevated expression of inducible nitric oxide synthase and inflammatory cytokines in the alveolar macrophages after esophagectomy. Crit Care Med 2002; 30:71-76.
12. Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 1999; 177:78-82.
13. N akanishi K, Takeda S, Terajima K, Takano T, Ogawa R. Myocardial dysfunction associated with proinflammatory cytokines after esophageal resection. Anesth Analg 2000; 91:270-275.
14. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155:1187-1205.
15. Reid PT, Donnelly SC, Haslett C. Inflammatory predictors for the development of the adult respiratory distress syndrome. Thorax 1995; 50:1023-1026.
16. Fujishima S, Sasaki J, Shinozawa Y, Takuma K, Hori S, Aikawa N. Interleukin 8 in ARDS. Lancet 1993; 342:237-238.
17. Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Brückner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg 2000; 135:291-295.
18. 1 protects liver from ischemic damage. J Surg Res 1994; 57:380-384.
19. 1 administration in cirrhotic rats. Gastroenterology 1993; 105:1483-1489.
20. 3. Immunology 1992; 76:251-257.
21. Oda K, Akiyama S, Ito K, Kasai Y, Fujiwara M, Sekiguchi H et al. Perioperative prostaglandin E1 treatment for the prevention of postoperative complications after esophagectomy: a randomized clinical trial. Surg Today 2004; 34:662-667.
22. Gupta S. Immune response following surgical trauma. Crit Care Clin 1987; 3:405-415.
23. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-687.
24. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997; 84:920-935.
25. Y ao YM, Redl H, Bahrami S, Schlag G. The inflammatory basis of trauma/shock associated multiple organ failure. Inflamm Res 1998; 47:201-210.
26. Sullivan TJ, Parker KL, Stenson W, Parker CW. Modulation of cyclic AMP in purified rat mast cells I. Responses to pharmacologic, metabolic, and physical stimuli. J Immunol 1975; 114:1473-1479.
27. Mansour KA, Downey RS. Esophageal carcinoma: surgery without preoperative adjuvant chemotherapy. Ann Thorac Surg 1989; 48:201-205.
28. Davies MG, Hagen PO. The vascular endothelium. Ann Surg 1993; 218:593-609.
29. Hooper TL, Thomson DS, Jones MT, Cook L, Owen S, Wilkes S et al. Amelioration of lung ischemic injury with prostacyclin. Transplantation 1990; 49:1031-1035.
30. Cranshaw J, Griffiths MJD, Evans TW. The pulmonary physician in critical care: Non-ventilatory strategies in ARDS. Thorax 2002; 57:823-829.
31. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL. A novel inhibitory prostanoid receptor piglet saphenous vein. Prostaglandins 1994; 47:151-168.
32. 2a on the changes in the adenylate cyclase activities of rabbit urinary tract tissues. J Smooth Muscle Res 1993; 29:29-36.
33. 1 prevents increased lung microvascular permeability during intravascular complement activation in sheep. Circ Res 1987; 61:420-428.
34. 1 on circulation, respiration and body temperature during surgical anesthesia. Masui 1997; 46:363-372.
35. 1 in liver transplantation. Hepatology 1995; 21:366-372.
36. Klein AS, Cofer JB, Pruett TL, Thuluvath PJ, McGory R, Uber L et al. Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterology 1996; 111:710-715.
37. 1, prevents thiamylal-fentanyl-induced bronchoconstriction in humans. Anesth Analg 2003; 97:456-460.
38. 1 infusion reduces impaired platelet aggregation after reperfusion in orthotopic liver transplantation. Transplantation 1993; 55:819-826.
39. 1 for prevention and treatment of ARDS after surgery. In: Vincent JL, ed. Update in Intensive Care and Emergency Medicine. Berlin: Springer Company 1989. p. 80-85.
40. Dixon D. Treatment Covariate Interaction. In: Armitage P, Colton T, ed. Encyclopedia of Biostatistics. Chichester: John Wiley & Sons Ltd 1998. p. 4559-4561.
41. 1 on plasma cytokine levels during pneumonectomy. Masui 1996; 45:304-308.
42. 1 improves antimicrobial and inflammatory responses in alveolar immune cells. Crit Care Med 2001; 29:1943-1949.